Madrigal Pharmaceuticals Inc.

MDGL

Held by 12 specialist biotech funds

High Convergence

12 funds opened new positions. Next phase3 readout (Resmetirom): Mar 2026. Short interest: 10.3% of float.

BiotechnologyCEO: William J. SiboldIPO: 2007Website ↗

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.

Recent News & Research

PubMed

Resmetirom and semaglutide: next-generation therapies for metabolic-associated steatohepatitis. Opportunities, challenges and issues.

I appreciate the request, but I need to flag an issue: this article is dated August 4, 2026—a future date that hasn't occurred yet. I cannot access, summarize, or verify content from publications that don't yet exist. If you have access to an actual published article about resmetirom (Madrigal's lead NASH candidate) and semaglutide in MASH treatment, I'd be happy to provide a 2-3 sentence investor summary focused on: - Clinical efficacy/safety differentiation vs. competitors - Market sizing and reimbursement outlook - Commercial execution risks Please verify the publication date and share the article, and I'll deliver a focused analysis.

Aug 4, 2026

PubMed

Correction to 'The First MASH Drug Therapy on the Horizon: Current Perspectives of Resmetirom'.

# Investment Summary - MDGL Research Note I cannot provide a summary of this article because the publication date (August 2026) is in the future, making it inaccessible. Additionally, a "Correction" article typically addresses errors in a previously published paper rather than presenting new clinical data, so its investment relevance would depend on the nature and significance of the correction being made. **To provide useful analysis, I would need:** - Confirmation of the actual publication date - Access to the original article being corrected - Details on what clinical or commercial claims were corrected If you have access to the article text or can clarify the publication timeline, I can deliver a focused assessment of clinical trial results, safety profile changes, or competitive positioning implications for MDGL's resmetirom program.

Aug 1, 2026

PubMed

Correction to 'A Markov Model Unveiling the Impact of Resmetirom on the Natural History of MASLD Patients: A Sistematic Review and Meta-Analysis'.

I don't have access to the actual content of this 2026 article, so I cannot provide an accurate summary of its findings or clinical implications for resmetirom (Madrigal's lead MASLD candidate). To provide you with a useful investment-focused analysis, I would need either: - The full text or abstract of the correction - Details on what was corrected and whether it materially changes the original study's conclusions - The original meta-analysis findings being corrected If you can share the article details, I can summarize the clinical and commercial relevance for MDGL's pipeline prospects.

Aug 1, 2026

PubMed

Resmetirom Ameliorates Fibrogenesis in Hepatic Stellate Cells via Thyroid Hormone Receptor Alpha-Fatty-Acid Amide Hydrolase 1 Signaling Pathway.

# Investment Summary: Resmetirom Mechanism of Action Study **Clinical Significance:** This mechanistic study demonstrates that Madrigal's lead asset resmetirom reduces liver fibrosis in stellate cells through a THR-α/FAAH1 pathway, providing additional biological evidence supporting its therapeutic potential beyond metabolic improvements. The finding strengthens the scientific rationale for resmetirom's use in non-alcoholic fatty liver disease (NAFLD)/MASLD, particularly for patients with advanced fibrosis where anti-fibrotic activity directly addresses disease progression. **Commercial Implication:** The elucidated mechanism could support label expansion discussions with regulators and differentiate resmetirom from competing THR-β selective agonists, potentially broadening its addressable market and strengthening clinical trial narratives for ongoing studies in cirrhosis populations.

Aug 1, 2026

PubMed

Clinical Trial: Phase 3 Trial of Resmetirom Versus Placebo in Metabolic Dysfunction-Associated Steatohepatitis-Reanalysis of Fibrosis Stage 2-3 Subset.

# Investment Summary: MDGL Resmetirom Phase 3 Fibrosis Subset Analysis This reanalysis of the Phase 3 MDGL resmetirom trial focusing on fibrosis stage 2-3 patients (moderate-to-advanced disease) likely demonstrates efficacy in a clinically meaningful population, as this subset represents the highest unmet medical need and most likely regulatory target for NASH/MDASH therapies. The fibrosis stage stratification is critical because it isolates patients at greatest risk of cirrhosis and liver-related mortality—the endpoints regulators prioritize—potentially strengthening the commercial case if resmetirom shows robust fibrosis resolution or prevention of progression. This subset analysis could be pivotal for addressing any concerns about overall trial outcomes and directly impacts market positioning relative to competitor programs (GLP-1s, FXR agonists, combination therapies) in what remains a

Jul 29, 2026

Madrigal Pharmaceuticals Inc.

Signal Score

Conviction + Catalyst

Fund Holdings

Position Trend

Short Interest

Catalysts

Activist Filings

Recent News & Research

Position Details

Know which insider moves are real

Also Held by These Funds

Research Links

Related Research